Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for …
Feb 4, 2025 · This study aims to evaluate the efficacy and survival outcomes of tyrosine kinase inhibitor (TKI) versus chemotherapy rechallenge in third-line treatment for advanced mCRC …
Current Targeted Therapy for Metastatic Colorectal Cancer
Abstract Colorectal cancer (CRC) is the third most common type of cancer and the second leading cause of cancer deaths worldwide. Surgery or surgery plus radiotherapy and/or …
Lost in translation: Revisiting the use of tyrosine kinase inhibitors ...
Nov 1, 2022 · Patients with advanced or metastatic colorectal cancer ( (m)CRC) have limited effective treatment options resulting in high mortality rates. A better understanding of the …
Combination IO/TKI Strategies in Metastatic Colorectal Cancer
Mar 27, 2023 · A comprehensive review on combination strategies with immune checkpoint and tyrosine kinase inhibitors in patients with metastatic colorectal cancer.
Emerging tyrosine kinase inhibitors for the treatment of metastatic …
Abstract Introduction: Colorectal cancer (CRC) is a leading cause of cancer death worldwide. Over the last decade, the addition of antibodies that block the epidermal growth factor receptor …
Current Options for Third-Line Treatment of Metastatic Colorectal Cancer
Treatment Principles for Relapsed Metastatic Colorectal Cancer Previously, patients with metastatic CRC who relapsed after standard therapy had few options other than supportive care.
Protocol: Evaluation of tyrosine kinase inhibitors combined with ...
Apr 3, 2022 · This is the first study to try to evaluate the efficacy and safety of tyrosine kinase inhibitors (TKIs) in combination with antiprogrammed cell death protein 1 (anti-PD-1) antibody …
A real-world study: third-line treatment options for metastatic ...
Abstract Background Numerous third-line treatment options exist for colorectal cancer. This study aims to assess the efficacy and safety of third-line therapies, including TKIs (fruquintinib, …
High-dose short-term osimertinib treatment is effective in patient ...
Apr 3, 2024 · Most tyrosine kinase inhibitors (TKIs) have failed in clinical trials for metastatic colorectal cancer (mCRC). To leverage the additional lower-affinity targets that most TKIs …
STELLAR-303: randomized phase III study of zanzalintinib - PubMed
Jul 23, 2024 · Most patients with metastatic colorectal cancer (mCRC) have limited treatment options following standard-of-care therapy. VEGFR-tyrosine kinase inhibitors (TKIs) have …